LYVE1 Antikörper

Produktnummer ABIN1589924

Produktdetails anti-LYVE1 Antikörper

Target: LYVE1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1))

Reaktivität: Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser LYVE1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Frozen Sections) (IHC (fro))

Spezifität: Recombinant mouse soluble Lyve-1

Produktmerkmale: Chromosomal location: 7, 7F2
Produced from sera of rabbits immunized with highly pure recombinant mouse soluble LYVE-1 produced in insect cells. The recombinant soluble LYVE-1 consists of amino acid 24 (Ala) to 228 (Gly) and is fused to a C-terminal His-tag (6xHis).

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Western Blot: use 2-5 µg/mL, FACS: use 3-10 µg/mL, IF/IHC: applicable with cryo-sections.

Kommentare:

Rabbit IG Polyclonal Antibody

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: PBS

Handhabung: Centrifuge vial prior to opening.

Lagerung: -20 °C

Informationen zur Lagerung: The lyophilized antibody is stable at room temperature for up to 1 month. The reconstituted antibody is stable for at least two weeks at 2-8 °C. Frozen aliquots are stable for at least 6 months when stored at -20 °C.

Haltbarkeit: 6 months

Referenzen für anti-LYVE1 Antikörper (ABIN1589924)

Lohrberg, Wilting: "The lymphatic vascular system of the mouse head." in: Cell and tissue research, (2016) (PubMed).

Eshita, Ji, Onishi, Kobayashi, Mizuno, Yoshida, Kubota, Onishi: "Medicinal facilities to B16F10 melanoma cells for distant metastasis control with a supramolecular complex by DEAE-dextran-MMA copolymer/paclitaxel." in: Drug delivery and translational research, Vol. 5, Issue 1, pp. 38-50, (2015) (PubMed).

Pang, Georgoudaki, Lambut, Johansson, Tabor, Hagikura, Jin, Jansson, Alexander, Nelson, Jakobsson, Betsholtz, Sund, Karlsson, Fuxe: "TGF-?1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis." in: Oncogene, (2015) (PubMed).

Wawrzyniak, Pich, Gross, Schütz, Fleury, Quemener, Sgandurra, Bouchaert, Moret, Mury, Rommens, Mottaz, Dombrowicz, Michalik: "Endothelial, but not smooth muscle, peroxisome proliferator-activated receptor ?/? regulates vascular permeability and anaphylaxis." in: The Journal of allergy and clinical immunology, Vol. 135, Issue 6, pp. 1625-35.e5, (2015) (PubMed).

Grzegorek, Drozdz, Chmielewska, Gomulkiewicz, Jablonska, Piotrowska, Karczewski, Janczak, Podhorska-Okolow, Dziegiel, Szuba: "Arterial wall lymphangiogenesis is increased in the human iliac atherosclerotic arteries: involvement of CCR7 receptor." in: Lymphatic research and biology, Vol. 12, Issue 4, pp. 222-31, (2014) (PubMed).

Quagliata, Klusmeier, Cremers, Pytowski, Harvey, Pettis, Thiele, Sleeman: "Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model." in: Clinical & experimental metastasis, Vol. 31, Issue 3, pp. 351-65, (2014) (PubMed).

Maruyama, Maruyama, Kato, Kajiya, Moritoh, Yamamoto, Matsumoto, Sawane, Kerjaschki, Nakazawa, Kinoshita: "The effect of podoplanin inhibition on lymphangiogenesis under pathological conditions." in: Investigative ophthalmology & visual science, Vol. 55, Issue 8, pp. 4813-22, (2014) (PubMed).

Augsten, Sjöberg, Frings, Vorrink, Frijhoff, Olsson, Borg, Östman: "Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties." in: Cancer research, Vol. 74, Issue 11, pp. 2999-3010, (2014) (PubMed).

Ji, Eshita: "Rapamycin inhibition of CFA-induced lymphangiogenesis in PLN is independent of mast cells." in: Molecular biology reports, Vol. 41, Issue 4, pp. 2217-28, (2014) (PubMed).

Padrón-Barthe, Temiño, Villa del Campo, Carramolino, Isern, Torres: "Clonal analysis identifies hemogenic endothelium as the source of the blood-endothelial common lineage in the mouse embryo." in: Blood, Vol. 124, Issue 16, pp. 2523-32, (2014) (PubMed).

Kraima, Derks, Smit, Van Munsteren, Van der Velden, Kenter, DeRuiter: "Lymphatic drainage pathways from the cervix uteri: implications for radical hysterectomy?" in: Gynecologic oncology, Vol. 132, Issue 1, pp. 107-13, (2014) (PubMed).

Hirosue, Vokali, Raghavan, Rincon-Restrepo, Lund, Corthésy-Henrioud, Capotosti, Halin Winter, Hugues, Swartz: "Steady-state antigen scavenging, cross-presentation, and CD8+ T cell priming: a new role for lymphatic endothelial cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 192, Issue 11, pp. 5002-11, (2014) (PubMed).

Berta, Hoda, Laszlo, Rozsas, Garay, Torok, Grusch, Berger, Paku, Renyi-Vamos, Masri, Tovari, Groger, Klepetko, Hegedus, Dome: "Apelin promotes lymphangiogenesis and lymph node metastasis." in: Oncotarget, Vol. 5, Issue 12, pp. 4426-37, (2014) (PubMed).

Watari, Shibata, Kawahara, Sata, Nabeshima, Shinoda, Abe, Azuma, Murakami, Izumi, Takahashi, Kage, Kuwano, Ono: "Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages." in: PLoS ONE, Vol. 9, Issue 6, pp. e99568, (2014) (PubMed).

Kilarski, Muchowicz, Wachowska, M??yk-Kope?, Golab, Swartz, Nowak-Sliwinska: "Optimization and regeneration kinetics of lymphatic-specific photodynamic therapy in the mouse dermis." in: Angiogenesis, Vol. 17, Issue 2, pp. 347-57, (2014) (PubMed).

Details zu LYVE1

Target: LYVE1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1))

Andere Bezeichnung: Lyve-1 (LYVE1 Produkte)

Synonyme: LYVE1 antikoerper, XLKD1 antikoerper, CRSBP-1 antikoerper, HAR antikoerper, LYVE-1 antikoerper, 1200012G08Rik antikoerper, Crsbp-1 antikoerper, Lyve-1 antikoerper, Xlkd1 antikoerper, lymphatic vessel endothelial hyaluronic receptor 1a antikoerper, lymphatic vessel endothelial hyaluronan receptor 1 antikoerper, lyve1a antikoerper, LYVE1 antikoerper, Lyve1 antikoerper

Hintergrund: LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41 % similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.
Synonyms: Lyve1, Xlkd1, Lyve-1, Crsbp-1, 1200012G08Rik

NCBI Accession: NP_444477, NM_053247

UniProt: Q8BHC0

Pathways: Glycosaminoglycan Metabolic Process